Kopran Limited (NSE:KOPRAN)

Market Cap	7.88B -14.1%
Revenue (ttm)	6.82B +8.3%
Net Income	257.31M -33.3%
EPS	5.33 -33.2%
Shares Out	n/a
PE Ratio	30.63
Forward PE	n/a
Dividend	3.00 (1.80%)
Ex-Dividend Date	Sep 4, 2025

Volume	281,224
Average Volume	592,720
Open	167.00
Previous Close	167.25
Day's Range	162.00 - 168.81
52-Week Range	107.00 - 212.58
Beta	0.76
RSI	55.75
Earnings Date	May 19, 2026

About Kopran

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti- helminthics, anti-acne, anti-infective, anti-thrombotic, s...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1958
• Employees: 1,024
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: KOPRAN

Financial Performance

In fiscal year 2026, Kopran's revenue was 6.81 billion, an increase of 8.23% compared to the previous year's 6.30 billion. Earnings were 257.31 million, a decrease of -33.26%.